CompletedPhase 4NCT00520234
Randomized Study of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in the Intensive Care Unit (ICU)
Studying Invasive candidiasis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mycoses Study Group
- Principal Investigator
- Luis Ostrosky-Zeichner, MDThe University of Texas Health Science Center, Houston
- Intervention
- Caspofungin(drug)
- Enrollment
- 222 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2007 – 2010
Study locations (12)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- University of Southern California, Los Angeles, California, United States
- University of Colorado, Denver, Colorado, United States
- Washington Hospital Center, Washington D.C., District of Columbia, United States
- Tulane University, New Orleans, Louisiana, United States
- Harper University Hospital/ Wayne State, Detroit, Michigan, United States
- Henry Ford Hospital, Detroit, Michigan, United States
- St. Patrick's Hospital, Missoula, Montana, United States
- Cooper University Hospital, Camden, New Jersey, United States
- The Ohio State University, Columbus, Ohio, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
- Medical Center of South Carolina, Charleston, South Carolina, United States
Collaborators
Merck Sharp & Dohme LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00520234 on ClinicalTrials.govOther trials for Invasive candidiasis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT05421858A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.Basilea Pharmaceutica
- RECRUITINGPHASE2NCT06194201A Trial of Intravenous HRS9432 in the Treatment of Subjects With Candidemia and/or Invasive CandidiasisFujian Shengdi Pharmaceutical Co., Ltd.
- RECRUITINGNCT06456151Invasive Candidiasis in Critical CareUniversity Hospital Ostrava
- RECRUITINGNANCT05763251Comparison of Uncomplicated Candidemia Therapy Duration in ChildrenArkansas Children's Hospital Research Institute
- ACTIVE NOT RECRUITINGPHASE3NCT04368559Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow TransplantationMundipharma Research Limited
- RECRUITINGNANCT03538912Early Discontinuation of Empirical Antifungal Therapy and BiomarkersUniversity Hospital, Lille